De La Vega Rodolfo E, van Griensven Martijn, Zhang Wen, Coenen Michael J, Nagelli Christopher V, Panos Joseph A, Peniche Silva Carlos J, Geiger Johannes, Plank Christian, Evans Christopher H, Balmayor Elizabeth R
Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, MN, USA.
cBITE, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, Netherlands.
Sci Adv. 2022 Feb 18;8(7):eabl6242. doi: 10.1126/sciadv.abl6242. Epub 2022 Feb 16.
Large segmental osseous defects heal poorly. Recombinant, human bone morphogenetic protein-2 (rhBMP-2) is used clinically to promote bone healing, but it is applied at very high doses that cause adverse side effects and raise costs while providing only incremental benefit. We describe a previously unexplored, alternative approach to bone regeneration using chemically modified messenger RNA (cmRNA). An optimized cmRNA encoding BMP-2 was delivered to critical-sized femoral osteotomies in rats. The cmRNA remained orthotopically localized and generated BMP locally for several days. Defects healed at doses ≥25 μg of BMP-2 cmRNA. By 4 weeks, all animals treated with 50 μg of BMP-2 cmRNA had bridged bone defects without forming the massive callus seen with rhBMP-2. Moreover, such defects recovered normal mechanical strength quicker and initiated bone remodeling faster. cmRNA regenerated bone via endochondral ossification, whereas rhBMP-2 drove intramembranous osteogenesis; cmRNA provides an innovative, safe, and highly translatable technology for bone healing.
大段骨缺损愈合不良。重组人骨形态发生蛋白-2(rhBMP-2)在临床上用于促进骨愈合,但它以非常高的剂量应用,会引起不良副作用并增加成本,同时仅提供有限的益处。我们描述了一种以前未被探索的、使用化学修饰信使核糖核酸(cmRNA)进行骨再生的替代方法。一种编码BMP-2的优化cmRNA被递送至大鼠的临界尺寸股骨截骨处。cmRNA在原位保持定位,并在局部产生BMP达数天。当BMP-2 cmRNA剂量≥25μg时缺损得以愈合。到4周时,所有接受50μg BMP-2 cmRNA治疗的动物均实现了骨缺损的桥接,且未形成rhBMP-2所见的大量骨痂。此外,此类缺损更快恢复正常机械强度,且更快启动骨重塑。cmRNA通过软骨内成骨实现骨再生,而rhBMP-2驱动膜内成骨;cmRNA为骨愈合提供了一种创新、安全且具有高度可转化性的技术。